Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS

30:40
 
Share
 

Manage episode 441927333 series 3562061
Content provided by Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Learn more about b-cell depletion, including Ocrevus, Kesimpta, Bonspri, Mabthera, Rituxan, and Briumvi, used for active RRMS, SPMS, and PPMS.

You can read the full article on my blog: https://ms-perspektive.com/080-b-cell-depletion

B-cell depletion therapies such as ocrelizumab (Ocrevus), ofatumumab (Kesimpta, Bonspri), rituximab (Mabthera, Rituxan) and ublituximab (Briumvi) have become important tools in the treatment of multiple sclerosis (MS). These treatments specifically target and deplete B cells, a type of immune cell involved in the inflammatory process of MS. B-cell therapies are considered to be some of the most specific and potent disease-modifying therapies (DMTs) available today, offering a tailored approach to reducing disease activity and progression. In this blog, we will explore how these therapies are classified within MS treatment options and what their approval status and efficacy mean for different patient populations.

Please remember that I can only provide an overview here. Your neurologist and your MS nurse should advise you in detail on the right therapy for you. This is because they know your general state of health and you should also talk about your goals, wishes, fears and preferences so that these can be taken into account.

Table of Contents Sources

I used the following sources to create the content:

---

You may also want to look at the posts on the other DMTs:

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

  continue reading

104 episodes

Artwork
iconShare
 
Manage episode 441927333 series 3562061
Content provided by Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Learn more about b-cell depletion, including Ocrevus, Kesimpta, Bonspri, Mabthera, Rituxan, and Briumvi, used for active RRMS, SPMS, and PPMS.

You can read the full article on my blog: https://ms-perspektive.com/080-b-cell-depletion

B-cell depletion therapies such as ocrelizumab (Ocrevus), ofatumumab (Kesimpta, Bonspri), rituximab (Mabthera, Rituxan) and ublituximab (Briumvi) have become important tools in the treatment of multiple sclerosis (MS). These treatments specifically target and deplete B cells, a type of immune cell involved in the inflammatory process of MS. B-cell therapies are considered to be some of the most specific and potent disease-modifying therapies (DMTs) available today, offering a tailored approach to reducing disease activity and progression. In this blog, we will explore how these therapies are classified within MS treatment options and what their approval status and efficacy mean for different patient populations.

Please remember that I can only provide an overview here. Your neurologist and your MS nurse should advise you in detail on the right therapy for you. This is because they know your general state of health and you should also talk about your goals, wishes, fears and preferences so that these can be taken into account.

Table of Contents Sources

I used the following sources to create the content:

---

You may also want to look at the posts on the other DMTs:

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

  continue reading

104 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play